Clinical implications of p53 mutations analysis in bladder cancer tissue and urine sediment by functional assay in yeast

Carcinogenesis

Volumn 25, Issue 12, 2004, Pages 2319-2323

  Schlichtholz, Beata ^a   Presler, Malgorzata ^a   Matuszewski, Marcin ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; FEMALE; FISHER EXACT TEST; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; MULTIVARIATE ANALYSIS; NON INVASIVE MEASUREMENT; NONHUMAN; PREDICTION; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE; URINE SEDIMENT; YEAST;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; MITOTIC INDEX; MUTATION; NEOPLASM STAGING; SACCHAROMYCES CEREVISIAE; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 10344245021     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/bgh256     Document Type: Article

References (30)

1. Ferlay,J., Bray,F., Pisani,P. and Parkin,D.M. (2001) Globocan 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC CancerBase No. 5. IARC, IARC Scientific Publications, Lyon.
2. Kiemeney,L.A., Witjes,J.A., Heijbroek,R.P., Verbeek,A.L. and Debruyne,F.M. (1993) Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J. Urol., 150, 60-64.
3. Fujimoto,K., Yamada,Y., Okajima,E., Kakizoe,T., Sasaki,H., Sugimura,T. and Terada,M. (1992) Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res., 52, 1393-1398.
4. Sidransky,D., Von Eschenbach,A., Tsai,Y.C., Jones,P., Summerhayes,I., Marshall,F., Paul,M., Green,P., Hamilton,S.R. and Frost,P. (1991) Identification of p53 gene mutations in bladder cancers and urine samples. Science, 252, 706-709.
5. Sarkis,A.S., Dalbagni,G., Cordon-Cardo,C., Melamed,J., Zhang,Z.F., Sheinfeld,J., Fair,W.R., Herr,H.W. and Reuter,V.E. (1994) Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J. Urol., 152, 388-392.
6. Duddy,P.M., Hanby,A.M., Barnes,D.M. and Camplejohn,R.S. (2000) Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay. J. Mol. Diagn., 2, 139-144.
7. Waridel,F., Estreicher,A., Bron,L., Flaman,J.M., Fontolliet,C., Monnier,P., Frebourg,T. and Iggo,R. (1997) Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract. Oncogene, 14, 163-169.
8. Gao,C., Ohashi,R., Pu,H., Inoue,Y., Tsuji,T., Miyazaki,M. and Namba,M. (1999) Yeast functional assay of the p53 gene status in 11 cell lines and 26 surgical specimens of human hepatocellular carcinoma. Oncol. Rep., 6, 1267-1271.
9. Pavlova,S., Mayer,J., Koukalova,H. and Smardova,J. (2003) High frequency of temperature-sensitive mutations of p53 tumor suppressor in acute myeloid leukemia revealed by functional assay in yeast. Int. J. Oncol., 23, 121-131.
10. Pfister,C., Flaman,J.M., Martin,C., Grise,P. and Frebourg,T. (1999) Selective detection of inactivating mutations of the tumor suppressor gene p53 in bladder tumors. J. Urol., 161, 1973-1975.
11. Sobin,L.H. and Fleming,I.D. (1997) TNM Classification of Malignant Tumors, 5th edn. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer, 80, 1803-1804.
12. Flaman,J.M., Frebourg,T., Moreau,V. et al. (1995) A simple p53 functional assay for screening cell lines, blood, and tumors. Proc. Natl Acad. Sci. USA, 92, 3963-3967.
13. Ishioka,C., Frebourg,T., Yan,Y.X., Vidal,M., Friend,S.H., Schmidt,S. and Iggo,R. (1993) Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nature Genet., 5 124-129.
14. Hoffman,C.S. and Winston,F. (1987) A ten-minute DNA preparation from yeast efficiently releases autonomous plasmids for transformation of Escherichia coli. Gene, 57, 267-272.
15. Cho,Y., Gorina,S., Jeffrey,P.D. and Pavletich,N.P. (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science, 265, 346-355.
16. Hainaut,P., Hernandez,T., Robinson,A., Rodriguez-Tome,P., Flores,T., Hollstein,M., Harris,C.C. and Montesano,R. (1998) IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res., 26, 205-213.
17. Olivier,M., Eeles,R., Hollstein,M., Khan,M.A., Harris,C.C. and Hainaut,P. (2002) The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat., 19, 607-614.
18. Marin,M.C., Jost,C.A., Brooks,L.A. et al. (2000) A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nature Genet., 25, 47-54.
19. Curigliano,G., Ferretti,G., Flamini,G. et al. (2001) Diagnosis of T1 bladder transitional cell carcinoma by denaturing gradient gel electrophoresis urinalysis. Anticancer Res., 21, 3015-3020.
20. Sidransky,D., Frost,P., Von Eschenbach,A., Oyasu,R., Preisinger,A.C. and Vogelstein,B. (1992) Clonal origin bladder cancer. N. Engl. J. Med., 326, 737-740.
21. Paiss,T., Wohr,G., Hautmann,R.E., Mattfeldt,T., Muller,M., Haeussler,J. and Vogel,W. (2002) Some tumors of the bladder are polyclonal in origin. J. Urol., 167, 718-723.
22. Hartmann,A., Rosner,U., Schlake,G., Dietmaier,W., Zaak,D., Hofstaedter,F. and Knuechel,R. (2000) Clonality and genetic divergence in multifocal low-grade superficial urothelial carcinoma as determined by chromosome 9 and p53 deletion analysis. Lab. Invest., 80, 709-718.
23. Prescott,J.L., Montie,J., Pugh,T.W., McHugh,T. and Veltri,R.W. (2001) Clinical sensitivity of p53 mutation detection in matched bladder tumor. Bladder wash, and voided urine specimens. Cancer, 91, 2127-2135.
24. Dahse,R., Utting,M., Werner,W., Schimmel,B., Claussen,U. and Junker,K. (2002) TP53 alterations as a potential diagnostic marker in superficial bladder carcinoma and in patients serum, plasma and urine samples. Int. J. Oncol., 20, 107-115.
25. Maquat,L.E. (1996) Defects in RNA splicing and the consequence of shortened translational reading frames. Am. J. Hum. Genet., 59, 279-286.
26. Muhlrad,D. and Parker,R. (1999) Recognition of yeast mRNAs as 'nonsense containing' leads to both inhibition of mRNA translation and mRNA degradation: implications for the control of mRNA decapping. Mol. Biol. Cell, 10, 3971-3978.
27. Spruck,C.H.,III, Rideout,W.M.,III, Olumi,A.F., Ohneseit,P.F., Yang,A.S., Tsai,Y.C., Nichols,P.W., Horn,T., Hermann,G.G. and Steven,K. (1993) Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage. Cancer Res., 53, 1162-1166.
28. Bernardini,S., Adessi,G.L., Chezy,E., Billerey,C., Carbillet,J.P. and Bittard,H. (2001) Influence of cigarette smoking on P53 gene mutations in bladder carcinomas. Anticancer Res., 21 3001-3004.
29. Denissenko,M.F., Pao,A., Tang,M. and Pfeifer,G.P. (1996) Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science, 274, 430-432.
30. Taylor,J.A., Li,Y., He,M., Mason,T., Mettlin,C., Vogler,W.J., Maygarden,S. and Liu,E. (1996) p53 mutations in bladder tumors from arylamine-exposed workers. Cancer Res., 56, 294-298.